Elsevier

Preventive Medicine

Volume 51, Issues 3–4, September–October 2010, Pages 228-233
Preventive Medicine

Review
Vitamin D and cardiovascular disease: Systematic review and meta-analysis of prospective studies

https://doi.org/10.1016/j.ypmed.2010.06.013Get rights and content

Abstract

Background

Low serum 25-hydroxyvitamin D (25-OH-D) has recently been linked to cardiovascular diseases. This review summarizes evidence from prospective studies evaluating the prognostic value of 25-OH-D for cardiovascular disease incidence and mortality.

Method

A systematic literature search in EMBASE and Pubmed-Medline databases was performed until November 2009. Prospective studies published in English were selected reporting estimates for the association of 25-OH-D with primary or secondary cardiovascular event incidence or mortality in the general population or subjects with prevalent cardiovascular disease. Pooled risk estimators were derived by meta-analysis using a random effects model approach.

Results

Four incidence and five independent mortality studies were included. Two incidence and three mortality studies reported a two- to five-fold risk increase for both outcomes in subjects with lower 25-OH-D, while the others did not detect a significant association. Meta-analysis supported the existence of an inverse association.

Conclusion

Data from prospective investigations suggest an inverse association between 25-OH-D and cardiovascular risk. However, given the heterogeneity and small number of longitudinal studies, more research is needed to corroborate a potential prognostic value of 25-OH-D for cardiovascular disease incidence and mortality.

Introduction

Vitamin D, primarily known for its essential role in bone metabolism, has recently been linked to various diseases including cancer, autoimmune or infectious diseases (Holick, 2007, Maalouf, 2008). Furthermore, cross-sectional and case–control studies have suggested a potential role of 25-hydroxyvitamin D (25-OH-D), the major circulating form of vitamin D, in risk reduction of cardiovascular diseases (CVD) (Hintzpeter et al., 2008, Kendrick et al., 2009, Scragg et al., 1990). Although the underlying biological causes are not fully understood, the association of 25-OH-D with cardiovascular pathology is speculated to be driven by various mechanisms: apart from a potential direct impact on cardiomyocytes and myocardial diseases (Pilz et al., in press), it has been suggested that 25-OH-D indirectly modifies CVD risk (Michos and Melamed, 2008) by its association with cardiovascular risk factors like diabetes (Martins et al., 2007, Mattila et al., 2007), obesity (Aasheim et al., 2008, Martins et al., 2007), hypertension (Forman et al., 2007, Kim et al., in press), smoking (Brot et al., 1999, Hill et al., 2006), or cholesterol level (Auwerx et al., 1992, Scragg et al., 1995).

Although calcitriol (1,25-(OH)2-D) is the active form of vitamin D, in the investigation of associations of vitamin D with incident cardiovascular events, serum-25-OH-D is generally used. Not only is the latter the substrate for 1-alpha-hydroxylase which produces intracellular calcitriol and is expressed in relevant tissues like cardiomyocytes (Pilz et al., in press) and the vessel wall (Somjen et al., 2005), it also is the major form circulating in serum and has been shown to be a better marker of vitamin D status (Holick, 1990, Maalouf, 2008). Longitudinal data on these relationships remain scarce.

Since cardiovascular diseases account for more deaths worldwide than any other disease (Lopez et al., 2006) while at the same time hypovitaminosis D is widespread in many populations (Ginde et al., 2009a, Prentice, 2008) and established risk factors insufficiently explain CVD occurrence (Greenland et al., 2003, Ridker, 1999, Wang et al., 2006), it would be desirable to elucidate possible associations of 25-OH-D with CVD and prognosis in order to explore further potential for CVD prevention. We therefore conducted a systematic review of prospective studies reporting on the association of serum 25-OH-D with cardiovascular disease risk.

Section snippets

Methods

A systematic literature search was performed by the first author (NCG) in the EMBASE (up to 13 November 2009) and Pubmed-Medline (up to 17 November 2009) databases, using the keywords vitamin D, cholecalciferol, calcidiol, calcitriol, 25-hydroxyvitamin D or 25-OH-D, connected by “AND” with the keywords cardiovascular diseases, cardiovascular, cardiovascular risk, cardiovascular system, coronary risk, ischemic heart disease, myocardial infarction, CHD, CAD, coronary heart disease, coronary

Literature search

The database search initially yielded 5019 results of which 695 duplicates were deleted (Fig. 1). From the remaining 4324 publications, 3949 were excluded because they were classified as not relevant to the topic after title and abstract review and another 63 because they were not published in English language. The remaining 312 references were full text reviewed, identifying 122 original articles. Of these, 3 animal studies were excluded. Other reasons for final exclusion were assessment of

Discussion

Five out of nine studies prospectively assessing the association between 25-OH-D and risk of incident CVD or mortality reported a significant increase in risk in subjects with lower 25-OH-D levels. The small number of studies fulfilling the rigorous inclusion criteria of our systematic review highlights the dearth of high-level evidence for the relationship examined.

Some inconsistencies in results were observed among both incidence and mortality studies which might, at least in part, be based

Conclusion

Prospective studies evaluating the prognostic value of 25-OH-D on cardiovascular disease outcomes in the general population or in populations with preexisting cardiovascular disease remain very rare. Overall, the published data seem to be in favor of an inverse association between 25-OH-D and cardiovascular risk. However, given the heterogeneity of eligible studies in terms of study population, outcome and exposure level definitions, there remains an urgent need for additional large-scale

Grant support

This work was supported in part by a grant from the Baden Württemberg Ministry of Research, Science and Arts. The funding source was not involved in any step of the analysis or the preparation or submission of the manuscript.

Conflict of interest statement

The authors declare that there are no conflicts of interest.

References (48)

  • A.D. Lopez et al.

    Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data

    Lancet

    (2006)
  • J. Marniemi et al.

    Dietary and serum vitamins and minerals as predictors of myocardial infarction and stroke in elderly subjects

    Nutr. Metab. Cardiovasc. Dis.

    (2005)
  • J.M. Valdivielso et al.

    Role of vitamin D receptor activators on cardiovascular risk

    Kidney Int. Suppl.

    (2008)
  • A.Y. Wang et al.

    Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study

    Am. J. Clin. Nutr.

    (2008)
  • A. Zittermann et al.

    Protective and toxic effects of vitamin D on vascular calcification: clinical implications

    Mol. Aspects Med.

    (2008)
  • P. Autier et al.

    Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials

    Arch. Intern. Med.

    (2007)
  • J. Auwerx et al.

    Relation between 25-hydroxyvitamin D3, apolipoprotein A-I, and high density lipoprotein cholesterol

    Arterioscler. Thromb. Vasc. Biol.

    (1992)
  • C. Brot et al.

    The influence of smoking on vitamin D status and calcium metabolism

    Eur. J. Clin. Nutr.

    (1999)
  • H. Dobnig et al.

    Independent association of low serum 25-hydroxyvitamin d and 1, 25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality

    Arch. Intern. Med.

    (2008)
  • A. Fahrleitner-Pammer et al.

    Bone markers predict cardiovascular events in chronic kidney disease

    J. Bone Miner. Res.

    (2008)
  • J.P. Forman et al.

    Plasma 25-hydroxyvitamin D levels and risk of incident hypertension

    Hypertension

    (2007)
  • A.A. Ginde et al.

    Demographic differences and trends of vitamin D insufficiency in the US population, 1988–2004

    Arch. Intern. Med.

    (2009)
  • A.A. Ginde et al.

    Prospective study of serum 25-hydroxyvitamin d level, cardiovascular disease mortality, and all-cause mortality in older U.S. Adults

    J. Am. Geriatr. Soc.

    (2009)
  • E. Giovannucci et al.

    25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study

    Arch. Intern. Med.

    (2008)
  • Cited by (217)

    • Hypovitaminosis D and cardiovascular outcomes: A systematic review and meta-analysis

      2022, IJC Heart and Vasculature
      Citation Excerpt :

      However, we found no significant association between HVD with all-cause mortality, risk of MI or heart failure. Previous reviews including observational studies demonstrated similar results as ours where HVD was associated with increased risk of cardiovascular (CV) events [2,6,8,24]. One of the studies further detailed the linear, inverse relation between circulating 25(OH)-vitamin D levels between 8 and 24 ng/mL and the risk of CV events [2].

    • Circulating 25-hydroxy-vitamin D and the risk of cardiovascular diseases. Systematic review and meta-analysis of prospective cohort studies

      2021, Nutrition, Metabolism and Cardiovascular Diseases
      Citation Excerpt :

      We uniquely examined CVD incidence as fatal, non-fatal and combined (fatal and non-fatal) events. In contrast, previous research has typically reported combined CVD estimates (fatal and non-fatal) [12–15]. Furthermore, to support the robustness of our findings, we adjusted the standard errors using the recommended Knapp-Hartung method [30], a practice not reported by previous research.

    View all citing articles on Scopus
    View full text